ReviewContributions to nephrology2017
Fibroblast Growth Factor 23: Mineral Metabolism and Beyond.
Review in Contributions to nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Association between bone mineral density and coronary artery calcification: an updated systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Trial
- Gut microbiota in a Saudi population with chronic kidney disease.World journal of nephrology · 2026Article
- Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm.Reviews in cardiovascular medicine · 2024Review
- Is there a role in acute kidney injury for FGF23 and Klotho?Clinical kidney journal · 2023Review
- Fibroblast Growth Factor 23 Signaling Does Not Increase Inflammation fromMedicina (Kaunas, Lithuania) · 2023Article
- Fibroblast Growth Factor Signaling in Development and Disease.International journal of molecular sciences · 2023Article
- Serum Intact Fibroblast Growth Factor 23 Levels Are Negatively Associated with Bone Mineral Density in Chronic Hemodialysis Patients.Journal of clinical medicine · 2023Article
- Article
- Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism.Endocrine connections · 2022Article
- Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment.Life (Basel, Switzerland) · 2021Review
- Vitamin D Effects on Bone Homeostasis and Cardiovascular System in Patients with Chronic Kidney Disease and Renal Transplant Recipients.Nutrients · 2021Review
- Toxin Removal and Inflammatory State Modulation during Online Hemodiafiltration Using Two Different Dialyzers (TRIAD2 Study).Methods and protocols · 2021Article
- Phosphate, Microbiota and CKD.Nutrients · 2021Review
- Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era.Calcified tissue international · 2021Review
- The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children.Biomarker insights · 2021Article
- Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Evaluation of serum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin, inflammation, and spinal damage.Rheumatology international · 2019Article
- Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF.Current molecular biology reports · 2019Article
- The Effects of the Anti-aging Protein Klotho on Mucociliary Clearance.Frontiers in medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients. The synthetic definition of CKD mineral and bone disorder (CKD-MBD) split the concept that the indexes of mineral metabolism extend their effects beyond the bone until the vascular wall and metabolic milieu of CKD patients through complex pathways. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy, CVD, inflammation, and chronic renal damage may help with the diagnosis and treatment of the systemic impairment that occurs secondary to CKD-MBD, thus slowing the progression of renal and CVD and improving patient survival. Recent insights into fibroblast growth factor (FGF) 23 have led to marked advancement in interpreting data on CVD and CKD progression ascribing to FGF23 a pivotal role in these pathologies independent of its co-receptor klotho and well beyond mineral metabolism. This review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.